Payment overview · 2025
General Payments
$1,461.17
83 reported records · 22 companies
Healthcare provider profile · identity verified
Gregory Healey, MD
Allopathic & Osteopathic Physicians|Family Medicine · CANTON, NY · NPI 1558372086
Verified facts
What the public records show
CMS Open Payments records show Gregory Healey, MD received $1,461.17 in general payments during 2025 across 83 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Aristada, Caplyta, Eliquis, Farxiga, Mounjaro, Nurtec Odt, Qulipta, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Synthroid by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Aristada by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 310 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 920 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Trelegy Ellipta by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Caplyta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 229 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 291 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 350 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 920 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $339.53 | 23.2% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $250.63 | 17.1% | 16 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $168.37 | 11.5% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $141.60 | 9.7% | 17 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $59.23 | 4.0% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $57.47 | 3.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.18 | 3.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $49.39 | 3.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $40.02 | 2.7% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $38.07 | 2.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.21 | 2.4% | 2 | 2025 |
| Fidia Pharma USA Inc. | Unresolved — no canonical attribution shown | $33.41 | 2.3% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $23.16 | 1.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.91 | 1.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.06 | 1.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.49 | 1.4% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $20.13 | 1.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.43 | 1.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.94 | 1.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.06 | 1.1% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $16.01 | 1.1% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $15.87 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,461.17 | 83 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $202.14 | 13 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $169.36 | 13 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $168.37 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $138.74 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $135.68 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $116.67 | 15 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $104.13 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $89.60 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $76.01 | 8 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $57.47 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $56.18 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $40.66 | 7 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $40.02 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $35.21 | 2 | 2025 |
Source payment records
|
|||||
| HYMOVIS Normalized: hymovis |
Device | Fidia Pharma USA Inc. | $33.41 | 2 | 2025 |
Source payment records
|
|||||
| BENEFIX Normalized: benefix |
Biological | PFIZER INC. | $24.93 | 2 | 2025 |
Source payment records
|
|||||
| HYMPAVZI Normalized: hympavzi |
Drug | PFIZER INC. | $24.93 | 2 | 2025 |
Source payment records
|
|||||
| XYNTHA Normalized: xyntha |
Biological | PFIZER INC. | $24.93 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $24.26 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.49 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.49 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| TRILURON Normalized: triluron |
Device | Fidia Pharma USA Inc. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $13.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ARISTADA aristada |
2025 | Aristada | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 920 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 310 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 229 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 153 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 214 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
119 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
106 | 27 |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | ARISTADA open payments reported associated product |
CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566 |
Aristada · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
28 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
310 | 77 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | 11 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
920 | 155 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
214 | 42 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
209 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
229 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
291 | 56 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
153 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
350 | 61 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
153 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
920 | 155 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
41 | 41 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1763 | 426 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1367 | 255 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1278 | 312 |
| Metoprolol Succinate | Metoprolol Succinate | 1215 | 270 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1155 | 287 |
| Amlodipine Besylate | Amlodipine Besylate | 1055 | 236 |
| Furosemide | Furosemide | 1044 | 245 |
| Omeprazole | Omeprazole | 942 | 229 |
| Eliquis | Apixaban | 920 | 155 |
| Gabapentin | Gabapentin | 907 | 159 |
| Lisinopril | Lisinopril | 830 | 188 |
| Losartan Potassium | Losartan Potassium | 815 | 193 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 674 | 109 |
| Tamsulosin Hcl | Tamsulosin Hcl | 660 | 158 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 652 | 78 |
| Oxycodone Hcl | Oxycodone Hcl | 608 | 77 |
| Metformin Hcl | Metformin Hcl | 559 | 145 |
| Escitalopram Oxalate | Escitalopram Oxalate | 519 | 116 |
| Prednisone | Prednisone | 518 | 272 |
| Trazodone Hcl | Trazodone Hcl | 517 | 121 |
| Metoprolol Tartrate | Metoprolol Tartrate | 509 | 116 |
| Montelukast Sodium | Montelukast Sodium | 490 | 105 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 410 | 124 |
| Simvastatin | Simvastatin | 381 | 84 |
| Quetiapine Fumarate | Quetiapine Fumarate | 376 | 52 |
| Potassium Chloride | Potassium Chloride | 366 | 81 |
| Clopidogrel | Clopidogrel Bisulfate | 354 | 78 |
| Duloxetine Hcl | Duloxetine Hcl | 350 | 79 |
| Ozempic | Semaglutide | 350 | 61 |
| Memantine Hcl | Memantine Hcl | 314 | 57 |
| Farxiga | Dapagliflozin Propanediol | 310 | 77 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 309 | 68 |
| Sertraline Hcl | Sertraline Hcl | 302 | 69 |
| Allopurinol | Allopurinol | 294 | 67 |
| Meloxicam | Meloxicam | 292 | 68 |
| Trulicity | Dulaglutide | 291 | 56 |
| Alprazolam | Alprazolam | 287 | 55 |
| Cefdinir | Cefdinir | 285 | 221 |
| Famotidine | Famotidine | 266 | 63 |
| Donepezil Hcl | Donepezil Hcl | 260 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 260 | 63 |
| Ezetimibe | Ezetimibe | 258 | 70 |
| Tramadol Hcl | Tramadol Hcl | 258 | 52 |
| Doxycycline Hyclate | Doxycycline Hyclate | 256 | 169 |
| Pregabalin | Pregabalin | 254 | 59 |
| Valsartan | Valsartan | 250 | 53 |
| Bupropion Xl | Bupropion Hcl | 238 | 48 |
| Mounjaro | Tirzepatide | 229 | 42 |
| Carvedilol | Carvedilol | 225 | 60 |
| Lorazepam | Lorazepam | 225 | 70 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 214 | 42 |
| Spironolactone | Spironolactone | 210 | 53 |
| Fluticasone Propionate | Fluticasone Propionate | 209 | 49 |
| Jardiance | Empagliflozin | 209 | 46 |
| Atenolol | Atenolol | 207 | 46 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 186 | 41 |
| Buspirone Hcl | Buspirone Hcl | 181 | 38 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 181 | 42 |
| Warfarin Sodium | Warfarin Sodium | 176 | 23 |
| Xarelto | Rivaroxaban | 173 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 172 | 49 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 168 | 36 |
| Topiramate | Topiramate | 165 | 34 |
| Amitriptyline Hcl | Amitriptyline Hcl | 163 | 37 |
| Metformin Hcl Er | Metformin Hcl | 159 | 43 |
| Lansoprazole | Lansoprazole | 158 | 34 |
| Nystatin | Nystatin | 158 | 73 |
| Azithromycin | Azithromycin | 155 | 98 |
| Fluconazole | Fluconazole | 155 | 88 |
| Rexulti | Brexpiprazole | 153 | 25 |
| Clonazepam | Clonazepam | 151 | 28 |
| Cephalexin | Cephalexin | 148 | 92 |
| Pravastatin Sodium | Pravastatin Sodium | 148 | 43 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 143 | 33 |
| Paroxetine Hcl | Paroxetine Hcl | 143 | 34 |
| Finasteride | Finasteride | 141 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 140 | 26 |
| Glimepiride | Glimepiride | 134 | 34 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 133 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 133 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 130 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 130 | 30 |
| Glipizide | Glipizide | 126 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 125 | 63 |
| Myrbetriq | Mirabegron | 122 | 21 |
| Sucralfate | Sucralfate | 121 | 37 |
| Linzess | Linaclotide | 119 | 23 |
| Celecoxib | Celecoxib | 117 | 35 |
| Bupropion Hcl Sr | Bupropion Hcl | 111 | 24 |
| Nebivolol Hcl | Nebivolol Hcl | 108 | 24 |
| Digoxin | Digoxin | 106 | 21 |
| Synthroid | Levothyroxine Sodium | 106 | 27 |
| Entresto | Sacubitril/Valsartan | 105 | 20 |
| Alendronate Sodium | Alendronate Sodium | 104 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 104 | 25 |
| Torsemide | Torsemide | 104 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 102 | 81 |
| Fluoxetine Hcl | Fluoxetine Hcl | 102 | 27 |
| Solifenacin Succinate | Solifenacin Succinate | 102 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 100 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 99 | 78 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 98 | suppressed |
| Baclofen | Baclofen | 96 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 96 | 25 |
| Mirtazapine | Mirtazapine | 96 | 18 |
| Carisoprodol | Carisoprodol | 95 | 14 |
| Diltiazem Hcl | Diltiazem Hcl | 95 | 14 |
| Indapamide | Indapamide | 91 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 24 |
| Ondansetron Odt | Ondansetron | 88 | 35 |
| Pioglitazone Hcl | Pioglitazone Hcl | 88 | 21 |
| Levetiracetam | Levetiracetam | 87 | 19 |
| Meclizine Hcl | Meclizine Hcl | 87 | 38 |
| Minocycline Hcl | Minocycline Hcl | 87 | 18 |
| Irbesartan | Irbesartan | 86 | 26 |
| Morphine Sulfate Er | Morphine Sulfate | 86 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 86 | 19 |
| Valacyclovir | Valacyclovir Hcl | 83 | 29 |
| Temazepam | Temazepam | 80 | 17 |
| Fenofibrate | Fenofibrate | 79 | 17 |
| Diazepam | Diazepam | 78 | 19 |
| Morphine Sulfate | Morphine Sulfate | 78 | 18 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 77 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 76 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 76 | 48 |
| Sumatriptan Succinate | Sumatriptan Succinate | 76 | 12 |
| Hydromorphone Hcl | Hydromorphone Hcl | 75 | 17 |
| Ibuprofen | Ibuprofen | 74 | 26 |
| Propranolol Hcl | Propranolol Hcl | 74 | 15 |
| Estradiol | Estradiol | 72 | 23 |
| Aripiprazole | Aripiprazole | 71 | 14 |
| Olanzapine | Olanzapine | 71 | 17 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 69 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 69 | 25 |
| Nystop | Nystatin | 68 | 30 |
| Rizatriptan | Rizatriptan Benzoate | 68 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 67 | 17 |
| Levofloxacin | Levofloxacin | 67 | 56 |
| Naproxen | Naproxen | 67 | 22 |
| Lidocaine | Lidocaine | 65 | 14 |
| Nitroglycerin | Nitroglycerin | 64 | 49 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 63 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 63 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 62 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 62 | 13 |
| Trintellix | Vortioxetine Hydrobromide | 58 | 11 |
| Ramipril | Ramipril | 57 | 17 |
| Doxepin Hcl | Doxepin Hcl | 56 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 56 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 55 | 13 |
| Enalapril Maleate | Enalapril Maleate | 54 | 15 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 53 | 15 |
| Glipizide Er | Glipizide | 53 | 14 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 53 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 17 |
| Lactulose | Lactulose | 52 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 52 | 11 |
| Ranolazine Er | Ranolazine | 51 | 12 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 51 | 16 |
| Dapagliflozin | Dapagliflozin Propanediol | 50 | 17 |
| Varenicline Tartrate | Varenicline Tartrate | 50 | 18 |
| Febuxostat | Febuxostat | 49 | 16 |
| Amoxicillin | Amoxicillin | 48 | 39 |
| Hydrocortisone | Hydrocortisone | 48 | suppressed |
| Lovastatin | Lovastatin | 48 | 11 |
| Chlorthalidone | Chlorthalidone | 47 | 11 |
| Methocarbamol | Methocarbamol | 47 | 17 |
| Novolog Flexpen | Insulin Aspart | 47 | 13 |
| Nucynta | Tapentadol Hcl | 47 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 46 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 45 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 45 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 44 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | 12 |
| Fentanyl | Fentanyl | 44 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 44 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 43 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 43 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 35 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 42 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 42 | 18 |
| Metoclopramide Hcl | Metoclopramide Hcl | 42 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 41 | 41 |
| Mupirocin | Mupirocin | 40 | 22 |
| Premarin | Estrogens, Conjugated | 40 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 39 | suppressed |
| Qulipta | Atogepant | 39 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | suppressed |
| Carbamazepine Er | Carbamazepine | 38 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 38 | 18 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 38 | suppressed |
| Lamotrigine | Lamotrigine | 38 | suppressed |
| Metronidazole | Metronidazole | 38 | 25 |
| Repatha Sureclick | Evolocumab | 38 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 36 | suppressed |
| Eszopiclone | Eszopiclone | 36 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 36 | suppressed |
| Loperamide | Loperamide Hcl | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Mesalamine | Mesalamine | 34 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 34 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 33 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 32 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 32 | suppressed |
| Methotrexate | Methotrexate Sodium | 32 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 32 | suppressed |
| Trospium Chloride | Trospium Chloride | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 31 | suppressed |
| Praluent Pen | Alirocumab | 31 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 30 | suppressed |
| Methimazole | Methimazole | 30 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 30 | 11 |
| Cilostazol | Cilostazol | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 29 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 29 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Mirabegron Er | Mirabegron | 28 | suppressed |
| Prolia | Denosumab | 28 | 18 |
| Terbinafine Hcl | Terbinafine Hcl | 28 | 20 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 27 | suppressed |
| Levemir Flexpen | Insulin Detemir | 27 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 27 | 13 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 27 | suppressed |
| Repatha Syringe | Evolocumab | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | 11 |
| Belsomra | Suvorexant | 25 | suppressed |
| Caplyta | Lumateperone Tosylate | 25 | suppressed |
| Phenobarbital | Phenobarbital | 25 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 25 | suppressed |
| Constulose | Lactulose | 24 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Methadone Hcl | Methadone Hcl | 24 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | 14 |
| Cholestyramine | Cholestyramine (With Sugar) | 23 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 23 | 15 |
| Nurtec Odt | Rimegepant Sulfate | 23 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 23 | suppressed |
| Captopril | Captopril | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 22 | 20 |
| Erythromycin | Erythromycin Base | 22 | suppressed |
| Oxycontin | Oxycodone Hcl | 22 | suppressed |
| Pentoxifylline | Pentoxifylline | 22 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 22 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 22 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Klor-Con M10 | Potassium Chloride | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Tobramycin | Tobramycin | 21 | 16 |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 20 | suppressed |
| Modafinil | Modafinil | 20 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Fluocinonide | Fluocinonide | 18 | suppressed |
| Phenytoin | Phenytoin | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Verapamil Sr | Verapamil Hcl | 18 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 18 | suppressed |
| Cyclosporine | Cyclosporine | 17 | suppressed |
| Dofetilide | Dofetilide | 17 | suppressed |
| Epinephrine | Epinephrine | 17 | 13 |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Acetazolamide | Acetazolamide | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 16 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 16 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 15 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 15 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 15 | suppressed |
| Protonix | Pantoprazole Sodium | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 14 | suppressed |
| Budesonide | Budesonide | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 14 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Nucynta Er | Tapentadol Hcl | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 14 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Enbrel Sureclick | Etanercept | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Invokamet Xr | Canagliflozin/Metformin Hcl | 13 | suppressed |
| Methylprednisolone Acetate | Methylprednisolone Acetate | 13 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 13 | suppressed |
| Opsumit | Macitentan | 13 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Aristada | Aripiprazole Lauroxil | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 12 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Codeine Sulfate | Codeine Sulfate | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Lamictal | Lamotrigine | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Provigil | Modafinil | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Diovan | Valsartan | 11 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 11 | suppressed |
| Hydromorphone Er | Hydromorphone Hcl | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 11 | suppressed |
| Savella | Milnacipran Hcl | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Striverdi Respimat | Olodaterol Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,461.17 · 83 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, ARISTADA, Auvelity, BENEFIX, BREZTRI, CAMZYOS, CAPLYTA, ELIQUIS, FARXIGA, FREESTYLE LIBRE 2, FREESTYLE LIBRE 3, GEMTESA, HYMOVIS, HYMPAVZI, IBSRELA, Kerendia, LYBALVI, MOUNJARO, NURTEC ODT, OTEZLA, Omnipod, QULIPTA, REPATHA, REXULTI, TRELEGY ELLIPTA, TRILURON, The Cologuard Plus Collection Kit, UBRELVY, VERQUVO, VYEPTI, Wegovy, XYNTHA, ZAVZPRET, ZEPBOUND | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Aristada play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error